Company Overview and News
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Crest Ventures is a diversified company having interest in real estate, financial services and investment and credit segment. It operates through its six subsidiaries, five associates companies and and joint venture company in above three segments. The company is involved in the development and management of various real estate properties, such as residential, commercial, and township properties.
511413 CREST BHARATGEAR 505688
Shares of Indian airlines bucked the weak trend in the overall market and posted gains on Thursday after the Government had agreed to cut the factory gate tax on jet fuel to 11 per cent from 14 per cent
INDIGO 532617 BHARATGEAR JETAIRWAYS 505688 539448
US stocks tumbled on Wednesday, with the S&P 500 and the Dow marking their biggest daily declines since February 8, and technology stocks were at the centre of the carnage as rising US Treasury yields sent investors fleeing from risky assets.
PRU NDAQ PRH PFK AAPL BHARATGEAR 505688 PJH
Banking stocks declined on Tuesday, pushing the Bank Nifty index lower on the back of renewed selling by domestic financial institutions. The Bank Nifty October contract was down 137.65 points and ended at 24,575. The underlying value of the contract closed at 24,527.65.
Shares of non-banking financial company (NBFC) Bajaj Finance rose sharply on Wednesday after SBI raised its target to buy “good quality” asset portfolios from NBFCs.
BAJFINANCE BHARATGEAR BJJQY 505688 500034
Bharat Dynamics has received orders worth about ₹200 crore from the Defence Research Development Organisation. The order is for supply of rear section of medium range surface to air missiles, which is a joint development project between the DRDO and Israel Aerospace Industries, with BDL as the nominated production agency. In the previous quarter ending June 2018, Bharat Dynamics had posted a net profit of ₹81.
The board of Bharat Gears has approved the rights issue of up to ₹15 crore to the existing shareholders of the company. The board has also authorised the existing Finance Committee to decide on the terms and conditions of the issue, including the issue size, issue price, timing of the issue, rights entitlement ratio, record date and all other matters, in consultation with the lead manager to the issue.
The margin financing business in India’s stock market has come to a virtual standstill. Leading high net worth individuals (HNIs), known for taking big derivative bets, are staring at a huge debt pile-up on account of the sharp fall of 25-70 per cent in the past couple of months in the share price of Titan, Tata Motors, VIP Industries, DHFL, Edelweiss Financial, Symphony, DLF, Aptech, Escorts, Bombay Dyeing, JP Associates and Kaveri Seeds, among others, according to promoters of two large Mumbai-based financial services firms, who did not want to be named.
BHARATGEAR 500570 532745 INDICAP 505688 TATAMOTORS TTM
Asian shares steadied in early Wednesday trade after world stocks hit eight-week lows the previous day on worries about global economic growth, although the pound stayed firm on hopes for a Brexit deal.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...